Table 3.
Study funding sources according to the articles
| Reference | Year of publication | Country/ies | Sponsoring companies |
|---|---|---|---|
| 13 | 2006 | Multicountry | AstraZeneca |
| 16 | 2006 | Sweden | AstraZeneca Sweden |
| 21 | 2003 | US | AstraZeneca Sweden |
| 25 | 1998 | UK | Glaxo Wellcome, UK Ltd. |
| 26 | 1998 | Germany | Glaxo Wellcome |
| 27 | 1996 | UK | Astra Pharmaceuticals Ltd. |
| 29 | 1999 | Germany | Glaxo Wellcome |
| 30 | 2000 | US | Glaxo Wellcome, Inc. |
| 31 | 2000 | UK | AstraZeneca Pharmaceuticals UK Ltd. |
| 32 | 2005 | Multicountry | AstraZeneca R&D; Lund |
| 36 | 1998 | Multicountry | Novartis |
| 37 | 1993 | Netherlands | Netherland’s Health Research Promotion Program (SGO), Glaxo,Astra Pharmaceuticals and Boehringer Ingelheim |
| 41 | 2002 | UK | GlaxoSmithKline Inc. |
| 42 | 2004 | US | GlaxoSmithKline Inc. |
| 43 | 2005 | Multicountry | GlaxoSmithKline Inc. |
| 45 | 2001 | US | GlaxoSmithKline Inc. |
| 47 | 2002 | US | GlaxoSmithKline Inc. |
| 48 | 2007 | Sweden | Novartis Pharma AG |
| 49 | 2006 | Multicountry | Novartis |
| 50 | 1996 | UK | Glaxo Wellcome resource |